

**Emeritus Professor Awtar Ganju-Krishan** obtained PhD in Zoology (cytogenetics) from the Panjab University, Chandigarh, India (1962) and a PhD in Micro-Anatomy from the Univ. of Western Ontario, Canada (1963). From 1965 to 1977, he was at the Sidney Farber Cancer Institute, Harvard Medical School, Boston, USA as Head of the Tissue Ultrastructure and Experimental Pathology Labs. He transferred to the University of Miami-School of Medicine and from 1980 to 1993 was Scientific Director of the Comprehensive Cancer Center. Most of his work has focused on avian cytogenetics, experimental therapeutics and analytical cytology. He developed flow cytometric techniques for rapid analysis of DNA content by the propidium iodide staining method, monitoring of fluorescent drug retention and resistance and for hormone receptor and marker expression in tumor cells. Some of his recent work has focused on monitoring of cell volume and marker expression in human stem cells from apheresis samples and body cavity fluids.



Dr. Krishan has organized cytometry workshops in Egypt, Turkey, Kuala Lumpur, Singapore and Shanghai. These activities are described in the website: <http://www.cytometryworkshops.com>. He is Co-Chair of the Education Committee and Chair of the Asia Task Force of the International Society for Advancement of Cytometry (ISAC).

#### **Relevant Literature:**

1. **Krishan A**, Sharma D, Sharma S, Hamelik RM, Ganjei-Azar P, Nadji M. ALDH(+)/CD44(+)/CD24(-) expression in cells from body cavity fluids. *Cytometry B Clin Cytom.* 2010 May;78(3):176-82.
2. **Krishan A**, Ganjei-Azar P, Hamelik R, Sharma D, Reis I, Nadji M. Flow immunocytochemistry of marker expression in cells from body cavity fluids. *Cytometry A.* 2010 Feb;77(2):132-43.
3. Hohla F, Buchholz S, Schally AV, **Krishan A**, Rick FG, Szalontay L, Papadia A, Halmos G, Koster F, Aigner E, Datz C, Seitz S. Targeted cytotoxic somatostatin analog AN-162 inhibits growth of human colon carcinomas and increases sensitivity of doxorubicin resistant murine leukemia cells. *Cancer Lett.* 2010 Aug 1;294(1):35-42.
4. Rick FG, Buchholz S, Schally AV, Szalontay L, **Krishan A**, Datz C, Stadlmayr A, Aigner E, Perez R, Seitz S, Block NL, Hohla F. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. *Cell Cycl.* 2012. 11: 2518-25.
5. Rick FG, Seitz S, Schally AV, Szalontay L, **Krishan A**, Datz C, Stadlmayr A, Buchholz S, Block L, Hohla F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. *Cell Cycle.* 2012 Nov 15;11(22):4203-10.